Skip to main content
ACTU
NASDAQ Life Sciences

Elraglusib Doubles Survival Rate in Pancreatic Cancer, Nature Medicine Publishes Pivotal Phase 2 Data

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$1.812
Mkt Cap
$43.152M
52W Low
$1.58
52W High
$11.99
52W Position info
15% above low
Off High info
85% below high
Rel. Volume info
1.7× avg
Market data snapshot near publication time

ACTU is trading near its 52-week low of $1.58 (15% above the low).

Summary

Actuate Therapeutics announced the publication of its Phase 2 clinical trial results for elraglusib in Nature Medicine, demonstrating a doubling of the one-year survival rate (44.1% vs 22.3%) and a 40% improvement in median overall survival (10.1 months vs 7.2 months) when combined with chemotherapy for previously untreated metastatic pancreatic cancer. The trial also showed a 38% reduction in the risk of death. This highly positive, peer-reviewed data is critical for Actuate, a small biopharmaceutical company with a market capitalization of approximately $43 million, especially given its recent 10-K filing (March 26, 2026) which included a going concern warning and indicated cash would only last until July 2026. The significant clinical benefit in a difficult-to-treat cancer could be a transformative catalyst, potentially facilitating partnerships, further financing, or accelerated regulatory pathways. Investors will closely monitor any developments regarding elraglusib's path forward and the company's ability to secure funding to extend its operational runway.

At the time of this announcement, ACTU was trading at $1.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $43.2M. The 52-week trading range was $1.58 to $11.99. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

ACTU - Latest Insights

ACTU
Nov 13, 2026, 5:01 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $0.2853
Real-time Price: $0.305 info
Change: +$0.0197 (+7%) info
Market Cap: $15.692M info
ACTU
Nov 13, 2026, 4:00 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.2853
Real-time Price: $0.305 info
Change: +$0.0197 (+7%) info
Market Cap: $15.692M info
ACTU
Oct 30, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.3351
Real-time Price: $0.305 info
Change: -$0.0301 (-9%) info
Market Cap: $15.692M info
ACTU
Oct 28, 2026, 5:17 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.3833
Real-time Price: $0.305 info
Change: -$0.0783 (-20%) info
Market Cap: $15.692M info
ACTU
Oct 28, 2026, 8:00 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $0.370
Real-time Price: $0.305 info
Change: -$0.065 (-18%) info
Market Cap: $15.692M info